Samsung Biologics posts solid Q2 earnings amid slight dip in sequential revenue

Samsung Biologics reported a solid performance for the second quarter of 2025, with strong year-on-year growth in key earnings metrics despite a modest decline in quarterly revenue compared to the previous quarter.

According to the company’s preliminary consolidated earnings report released on Wednesday, Samsung Biologics posted 1.29 trillion won ($934.4 million) in revenue for the second quarter, down 0.6 percent from the previous quarter but up 11.5 percent compared to the same period last year.

Operating profit came in at 475.6 billion won, marking a 2.3 percent decrease from the first quarter but a 9.5 percent increase from the second quarter of 2024, and net profit was 324.3 billion won, down 13.62 percent from the last quarter but a 2.01 percent increase from the same period last year.

In standalone terms, Samsung Biologics posted sales and operating profit of 1 trillion won and 477 billion won in the second quarter, up 25.2 percent and 44.9 percent, respectively.

The company attributed the earnings growth to improved operational efficiency across Plants 1 to 3 and the accelerated ramp-up of Plant 4, which began partial operations in October 2022.

However, Samsung Bioepis, its biosimilar arm, posted sales and operating profit of 401 billion won and 89.8 billion won, down 24.3 percent and 65.1 percent, year-on-year, respectively.

The company stressed that the decline was due to the recognition of 220.5 billion won in milestone payments during the second quarter of 2024. Excluding the milestone effect, revenue increased 28 percent year-on-year, reflecting continued growth driven by expanded pure product sales.